<span item_type="fundamental" item_id="e62b49379837dd5ec1dc783326e2c26f" counter_id="ST/US/CLNNW" env="prod"></span><span item_type="announcement" item_id="549330088996246529" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 27 K.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.78.</p><p></p><h3>Financial Metrics Summary</h3><h4>Cash and Cash Equivalents</h4><ul><li>As of June 30, 2025, Clene Inc. reported cash and cash equivalents of $7.3 million, a decrease from $12.2 million as of December 31, 2024. The company expects that its resources, along with $1.9 million raised in equity and a $1.5 million increase in its convertible debt facility, will be sufficient to fund operations into the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul><h4>Research and Development Expenses</h4><ul><li>Research and development expenses were $3.5 million for the quarter ended June 30, 2025, compared to $4.2 million for the same period in 2024. The decrease was primarily due to reduced personnel expenses and stock-based compensation, offset by increased expenses related to the ALS clinical programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul><h4>General and Administrative Expenses</h4><ul><li>General and administrative expenses were $2.4 million for the quarter ended June 30, 2025, down from $3.3 million for the same period in 2024. This decrease was mainly due to reduced personnel expenses, stock-based compensation, and legal fees, partially offset by increased finance and accounting fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Clene reported a net loss of $7.4 million, or $0.78 per share, for the quarter ended June 30, 2025, compared to a net loss of $6.8 million, or $1.06 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul><h4>Total Other Expense</h4><ul><li>Total other expense was $1.6 million for the quarter ended June 30, 2025, compared to total other income of $0.6 million for the same period in 2024. This change was primarily due to non-cash losses on derivative liabilities and common stock warrant liabilities, and decreased interest income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Clene plans to analyze neurofilament light data from its NIH-sponsored Early Access Protocol in the fourth quarter of 2025 and expects to submit a New Drug Application for CNM-Au8 in ALS by the end of 2025. The company anticipates that its current resources will fund operations into the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm"></span></li></ul>

CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q2 Revenue: USD 27 K